News : GMP

View:
 

Found press releases

 

New Michigan-based Medical Product Manufacturing Effort provides solutions for I...

May 22, 2013

The University of Michigan Pediatric Medical Device Consortium (M-PED) is launching a new medical product manufacturing video on Vimeo. This 28-minute video: “Innovative Pediatric Manufacturing: Strategies & Solutions – A Guide To Bringing Your Device To Market” features critical content on FDA manufacturing requirements for both pediatric and adult products. Two products...

XYMOGEN RECEIVES GOLD STANDARD FOR SAFETY, QUALITY IN MANUFACTURING

ORLANDO, Fla. — March 7, 2013 — Orlando-based nutraceutical company XYMOGEN announced today that its manufacturing facility has earned the prestigious NSF International Good Manufacturing Practices (GMP) and GMP for Sport Athletic Banned Substances Program registrations.

The GMP registration verifies that XYMOGEN has the proper methods, equipment, facilities and controls in place to produce dietary supplements....

Zuken’s PCB Design Suites Add Support for Xilinx's Zynq-7000 All Programmable So...

Zuken, a leader in PCB Systems and IC Package design, has announced support for Xilinx’s Zynq-7000 All Programmable SoCs within its CR-8000 and CR-5000 PCB design suites.
Zuken’s Graphical Pin Manager (GPM) FPGA and PCB co-design environment now includes Xilinx's Zynq-7000 All Programmable SoCs, and 7 series FPGAs, within its device library.

This...

George Köllner joins Syntagon Quality Assurance and regulatory team

Leading contract research provider, Syntagon, is delighted to announce that it has entered into a collaborative agreement with world-class Quality Assurance (QA) expert George Köllner.
George brings with him more than 20 years’ experience from the pharma industry. He has served as Director of Quality Assurance at AstraZeneca where he led the development and implementation of modern Quality Assurance systems in...

Syntagon introduces strategic pricing initiative

Leading contract research organisation, Syntagon, has unveiled a strategic pricing initiative that will see substantial cost savings for biotechnology and pharmaceutical customers taking compounds into phase I and phase II clinical trials.
“Now, more than ever, customers are under growing pressure to make their limited resources stretch further. Cost-efficiency is increasingly critical; and maintaining cash is...